Thursday, November 26, 2020

Sanofi says its vaccine won’t need supercooling

Maintaining the 'ultra-cold chain' from factory to patients is expected to present an enormous logistical challenge.

Other News

Kematian Maradona, Argentina berkabung 3 hari

Maradona meninggal dunia pada Rabu akibat serangan jantung di kediamannya di daerah Tigre, utara Buenos Aires.

MQA tarik balik lantikan ahli majlis terpalit tuduhan pecah amanah RM2.8 juta

Mohamed Zaini sudah dimaklumkan mengenai penarikan semula pelantikannya yang berkuat kuasa minggu lepas.

Putrajaya’s higher education authority revokes appointment of new member over RM2.8 million CBT charge

MQA says it views seriously the integrity of its council members.

Undi Belanjawan 2021 dijadual hari ini

Undian Rang Undang-undang Perbekalan 2021 akan dijalankan sejurus selepas baki sembilan menteri membuat penggulungan.

US hits 6-month high of over 2,400 virus deaths in 24 hours

The country has recorded a total of 262,080 Covid deaths, up by 2,439 in 24 hours.

The coronavirus vaccine being developed by Sanofi won’t need to be super-cooled and a normal refrigerator will suffice, the Paris-based drugmaker’s France chief Olivier Bogillot said Sunday.

His comments came days after American pharmaceutical giant Pfizer and its German partner BioNTech announced that their vaccine had proven 90% effective in preventing Covid-19 infections in ongoing Phase 3 trials involving more than 40,000 people.

The companies said they expect to supply up to 50 million vaccine doses globally in 2020, and up to 1.3 billion doses in 2021.

However, Pfizer’s vaccine must be stored at -70 degrees Celsius (-94 degrees Fahrenheit) or else it falls apart, well beyond the capability of most hospital freezers let alone domestic appliances.

Rachel Silverman, a policy fellow at the Center for Global Development, has already warned that maintaining the Pfizer vaccine’s “ultra-cold chain” from factory to patients’ arms constitutes “an enormous logistical challenge even in the West”.

“Our vaccine will be like the ‘flu vaccine, you can keep it in your refrigerator,” this avoiding the problem, Bogillot told the CNews channel.

“This will be an advantage for some countries,” he added.

The Sanofi vaccine, one of many in development, will be available for distribution next June, Bogillot added.

The results of the Phase 2 tests, involving hundreds of people, will be made public in early December, he added. If those results are positive then Phase 3 trials involving thousands of people will begin, alongside mass production.

Eleven of the vaccines under development have already begun Phase 3 trials.

The Pfizer vaccine is “a little more advanced” in the development process, said Bogillot, but “one laboratory is not going to be able to supply the doses for the whole planet.

“We will need to have several winners at the end of this race.”

The Sanofi product will also be made avaiable at an “affordable” price he said, without giving details.

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

US hits 6-month high of over 2,400 virus deaths in 24 hours

The country has recorded a total of 262,080 Covid deaths, up by 2,439 in 24 hours.

Pandemic or not, people must stay active, says WHO

'If we do not remain active, we run the risk of creating another pandemic of ill-health as a result of sedentary behaviour.'

Covid-19 cases worldwide top 60 million

In total 60,014,291 infections, leading to 1,415,258 deaths, have been recorded around the world since the pandemic emerged in China late last year.

970 new cases, recoveries hit high of 2,348

318 cases in Negeri Sembilan, 115 in Selangor.

Australia eyes vaccination entry requirement

Australia's Health Minister Greg Hunt has suggested that a vaccination or a strict two-week quarantine would be a condition for entry.